In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Lixisenatide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 768 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 164 (163 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 67 · 5 active9 more mention it but do not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Adlyxin says: “Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus” No central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Lixisenatide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 35334571 | 1,117 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 3333 | 83481717 |
|---|
| Adverse eventsWhole body | 117117 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 3838 | 185185 |
|---|
| Heart functionRespiratory | 16466 | 214198142 |
|---|
| LipidsMetabolic and weight | 99 | 14313733 |
|---|
| Cardiovascular eventsCardiovascular | 321 | 13313111 |
|---|
| Blood pressureCardiovascular | 981 | 1201182 |
|---|
| Kidney functionKidney and urinary | 25241 | 1049932 |
|---|
| Appetite and food intakeMetabolic and weight | 1091 | 1129517 |
|---|
| Inflammation markersNervous system and cognition | 1192 | 117100152 |
|---|
| PharmacokineticsPharmacology | 13112 | 969231 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Lixisenatide differs from Exenatide at 7 positions.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 67 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Sanofi6,068 participantsJun 2010 to Feb 2015
Acute Coronary Syndrome
Sanofi1,170 participantsFeb 2014 to Jun 2015
Type 2 Diabetes
Sanofi894 participantsJan 2013 to Dec 2014
Type 2 Diabetes
9 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Lixisenatide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | −0.4% Placebo-corrected HbA1c change from baseline Dose studied: 20 μg24 weeksn = 4952013 | −1.09% HbA1c difference Dose studied: 1.8 mg once daily26 weeksn = 3442009 |
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in kg | −1.12 kg Body weight change · lixisenatide, week 24 Placebo, week 24: 0.04 kg 24 weeksn = 4482018 | −4.5 kg Body weight change |
| Treatment adherence and retentionPharmacologyCompared as: value in the arm that got the peptide, in % | 86% Study completion Placebo: 92% Dose studied: 20 µg once daily24 weeksn not reported2012 | |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 16.3% Nausea Placebo: 2.6% Dose studied: 20 µg once daily24 weeksn = 3912014 | |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 63.8% Treatment-emergent adverse events Placebo: 40.8% 24 weeksn = 4482018 | 89% Adverse events Placebo: 88% |
−0.4%
Placebo-corrected HbA1c change from baseline
Dose studied: 20 μg24 weeksn = 4952013
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Lixisenatide | Liraglutide |
|---|---|---|
| Exercise and physical functionMusculoskeletalCompared as: difference from placebo, in points | 3.08 points Difference in MDS-UPDRS part III change 12 monthsn = 1562024 |
Dose studied: 1.8 mg/day26 weeksn = 502014
65%
Trial completion
Placebo: 53.4%
Dose studied: 3.0 mg/d56 weeksn = 1322025
21%
Nausea · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 9112013
Dose studied: 3.0 mg or maximum tolerated dose once daily56 weeksn = 822025
−1.12 kg
Body weight change · lixisenatide, week 24
Placebo, week 24: 0.04 kg
24 weeksn = 4482018
−4.5 kg
Body weight change
Dose studied: 1.8 mg/day26 weeksn = 502014
86%
Study completion
Placebo: 92%
Dose studied: 20 µg once daily24 weeksn not reported2012
65%
Trial completion
Placebo: 53.4%
Dose studied: 3.0 mg/d56 weeksn = 1322025
16.3%
Nausea
Placebo: 2.6%
Dose studied: 20 µg once daily24 weeksn = 3912014
21%
Nausea · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 9112013
63.8%
Treatment-emergent adverse events
Placebo: 40.8%
24 weeksn = 4482018
89%
Adverse events
Placebo: 88%
Dose studied: 3.0 mg or maximum tolerated dose once daily56 weeksn = 822025
No comparable result 20 randomized-trial results measure it in another way or another unit. |
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No comparable result 5 randomized-trial results measure it in another way or another unit. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
|---|
| Heart functionCardiovascularCompared as: difference from placebo, in % | No comparable result 4 randomized-trial results measure it in another way or another unit. | 4.7% Difference in LVEF change Dose studied: 0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days7 daysn = 902016 |
|---|
| Vascular functionCardiovascularCompared as: difference from placebo, in p-value | 0.38 p-value Between-group p value for Ao-PWV 24 weeksn = 902026 | No comparable result 25 randomized-trial results measure it in another way or another unit. |
|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in meals/day | No comparable result 2 randomized-trial results measure it in another way or another unit. | −1 meals/day Meal replacements per day difference Dose studied: 1.2 mg per dayn = 522015 |
|---|
| Gastrointestinal motilityGastrointestinalCompared as: difference from placebo, in % | No comparable result 11 randomized-trial results measure it in another way or another unit. | −31.7% Reduction in large bowel transit time · Shown as a change. The study reports a reduction in large bowel transit time of this size. Dose studied: 1.8 mg/day26 weeksn = 482020 |
|---|
| Kidney functionKidney and urinaryCompared as: difference from placebo, in % | No comparable result 19 randomized-trial results measure it in another way or another unit. | −32% UAER reduction · Shown as a change. The study reports a uaer reduction of this size. Dose studied: 1.8 mg/d12 weeksn = 272017 |
|---|
3.08 points
Difference in MDS-UPDRS part III change
12 monthsn = 1562024
No comparable result
20 randomized-trial results measure it in another way or another unit.
No comparable result
5 randomized-trial results measure it in another way or another unit.
21 lipids
Lipids decreased
26 weeksn = 1022021
No comparable result
4 randomized-trial results measure it in another way or another unit.
4.7%
Difference in LVEF change
Dose studied: 0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days7 daysn = 902016
0.38 p-value
Between-group p value for Ao-PWV
24 weeksn = 902026
No comparable result
25 randomized-trial results measure it in another way or another unit.
No comparable result
2 randomized-trial results measure it in another way or another unit.
−1 meals/day
Meal replacements per day difference
Dose studied: 1.2 mg per dayn = 522015
No comparable result
11 randomized-trial results measure it in another way or another unit.
−31.7%
Reduction in large bowel transit time · Shown as a change. The study reports a reduction in large bowel transit time of this size.
Dose studied: 1.8 mg/day26 weeksn = 482020
No comparable result
19 randomized-trial results measure it in another way or another unit.
−32%
UAER reduction · Shown as a change. The study reports a uaer reduction of this size.
Dose studied: 1.8 mg/d12 weeksn = 272017